According to a new report, published by KBV research, The Global Oral Antiviral Market size is expected to reach $41.2 billion by 2029, rising at a market growth of 2.3% CAGR during the forecast period.
The Hepatitis market is poised to grow at a CAGR of 2.6% during (2023 - 2029). Hepatitis A, B, and C are the most prevalent types of viral hepatitis, and they are all brought on by different types of hepatitis virus. In contrast to hepatitis B and C, which are spread by contact with blood or bodily fluids, hepatitis A is spread through contaminated food and water. Therefore, it is typical to use a mix of medications to treat chronic hepatitis C.
The Reverse Transcriptase Inhibitors market is leading the Global Oral Antiviral Market by Drug Class in 2022 thereby, achieving a market value of $21.1 billion by 2029. Given that these medications are primarily utilized for treating HIV infection and their high efficiency against viral infections, the large percentage of reverse transcriptase inhibitors can be related to the rising rate of HIV diagnosis and treatment.
The Hospital Pharmacies market has shown the high growth rate of 2.6% during (2023 - 2029). In both developing and developed nations, hospital pharmacies are the primary facilities for the detection and care of patients with viral infections. The segment's growth is predicted to be supported by the increasing prevalence of diseases and a consistent stream of hospital patients. In addition, a rise in the number of hospitals with pharmacies and suitable reimbursement codes is also driving this segment's expansion.
The North America market dominated the Global Oral Antiviral Market by Region in 2022 thereby, achieving a market value of $16,626.6 million by 2029. The Europe market is anticipated to grow at a CAGR of 1.9% during (2023 - 2029). Additionally, The Asia Pacific market would witness a CAGR of 3.2% during (2023 - 2029).
Full Report: https://www.kbvresearch.com/oral-antiviral-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Bristol Myers Squibb Company, Gilead Sciences, Inc., Viatris, Inc. (Mylan N.V.), AbbVie, Inc., GlaxoSmithKline PLC (GSK), Teva Pharmaceutical Industries Ltd., and Amneal Pharmaceuticals, Inc.
By Indication
By Drug Class
By Distribution Channel
By Geography
Companies Profiled
Unique Offerings 
